Copolymer artificial tear with ocular surface adhesion and oxidation resistance and application
By designing copolymer artificial tears and combining superhydrophilic zwitterionic and phenylboronic acid structural monomers, the problems of insufficient adhesion and antioxidant properties of existing artificial tears in dry eye symptoms have been solved, achieving a multifunctional therapeutic effect of long ocular surface retention and antioxidant properties.
Patent Information
- Application Number
- CN202410878541.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-02
- Publication Date
- 2024-11-01
AI Technical Summary
Existing artificial tears lack antioxidant function and have insufficient adhesion when treating dry eye symptoms, resulting in poor patient compliance and failing to effectively block oxidative stress damage and improve ocular surface function.
To develop a copolymer artificial tear that combines ocular surface adhesion and antioxidant properties, a PMPD copolymer is formed by copolymerizing a superhydrophilic zwitterionic monomer with a monomer containing phenylboronic acid structure. This copolymer binds specifically to sialic acid to achieve long ocular surface retention and antioxidant functions.
It improves the ocular surface adhesion and antioxidant capacity of artificial tears, enhances the therapeutic effect on dry eye symptoms, and optimizes patient compliance and treatment outcomes.
Smart Images

Figure CN118873554A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedical materials, and in particular to a copolymer artificial tear having the properties of eye surface adhesion and anti-oxidation and its application. Background Art
[0002] Dry eye is an ocular surface disease caused by multiple factors, characterized by tear film imbalance combined with multiple ocular symptoms. The global prevalence of dry eye is 5% to 50%. With the increase in exposure to risk factors for dry eye, such as video terminals, environmental pollution, contact lens wear, aging, hormone levels, immune diseases, etc., the incidence of dry eye is also increasing year by year. Dry eye can cause symptoms such as dryness of the ocular surface, foreign body sensation, photophobia, and pain, leading to decreased visual quality, blurred vision, visual fatigue, systemic symptoms, limiting life and labor, reducing quality of life, and affecting mental health. Dry eye has therefore become the most common cause of seeking eye care, bringing a heavy economic burden to individuals and society.
[0003] In the process of dry eye, insufficient tear secretion or excessive evaporation can cause insufficient tears, which can cause tear hyperosmosis, thereby stimulating the production of cytokines, matrix metalloproteinases (MMPs) and chemokines, inducing inflammation in ocular tissues, and at the same time, cells undergo oxidative stress during hyperosmotic stress. The ocular surface produces high levels of reactive oxygen species (ROS), but only low levels of antioxidant enzymes, lacking the participation of antioxidants, causing oxidative stress damage. In the vicious cycle of dry eye, insufficient tears and tear film imbalance are one of the main causes of dry eye. Tears play an important role in maintaining corneal transparency, building optical interfaces, and lubricating the ocular surface. Insufficient tears often cause dry eye discomfort and decreased visual quality. Insufficient tears cause hyperosmosis, which can cause oxidative stress and inflammation. Oxidative stress and inflammation are mutually causal and mutually stimulating. Oxidative stress damages proteins and DNA, causes lipid peroxidation, causes mitochondrial dysfunction, and leads to cell necrosis; ROS, as a signal molecule, is directly transmitted to organelles and nuclei, causing cell apoptosis. Therefore, oxidative stress damage destroys the structure of the ocular surface and causes loss of function. Inflammatory factors further damage the ocular surface microvilli, damage the ocular surface glycocalyx and goblet cells, and destroy the structure and function. The damage to the ocular surface function causes further reduction in tear secretion or excessive evaporation, and the cycle repeats.
[0004] The commonly used treatment for tear deficiency is artificial tear replacement therapy. Artificial tears have the function of moistening the ocular surface and improving tear hyperosmolarity. They are fast and effective in alleviating dry eye symptoms, and are the most commonly used method for treating dry eyes. Artificial tears often use water-soluble polymers as active ingredients. Currently, hyaluronic acid, polyethylene glycol (PEG), polyvinyl alcohol, cellulose derivatives, etc. are on sale. In addition, some new artificial tear polymer materials have gradually come into people's view, among which zwitterionic polymers have attracted the attention of researchers. Zwitterions have equal amounts of positive and negative charges, can bind water molecules through electrostatic effects, and have been proven to have better hydrophilicity than PEG.
[0005] ROS is an important upstream factor in the development of dry eye. The treatment of dry eye by removing ROS has attracted great attention from researchers and clinicians. The commercial drug SKQ1 (visomitin) and antioxidants such as acetylcysteine and vitamin A have been used to treat dry eye. A variety of free radical scavenging materials such as cerium oxide nanozymes have also been reported to be used to treat dry eye by blocking oxidative stress. Through the detection of the total antioxidant capacity of currently commercially available artificial tears, it was found that most artificial tears have no antioxidant effect, and a small amount of artificial tears have low or medium levels of antioxidant effect, which is not enough to block oxidative stress damage to the ocular surface. Artificial tears are often used in combination with drugs with antioxidant function in clinical practice, but different eye drops need to be used at an interval of 15 minutes or even longer, which is inconvenient for patients to use and is easy to misuse and abandon. At the same time, due to the rapid flushing of tears on the ocular surface, the bioavailability of artificial tears after eye drops is affected, and it often requires long-term and multiple eye drops. How to improve the ocular surface adhesion of artificial tears is of great significance to improving patient compliance. Targeted adhesion to ocular surface mucin is an effective means to increase the retention time of drugs on the ocular surface.
[0006] In summary, achieving both tear replenishment and antioxidant functions in one artificial tear while improving its ocular surface adhesion is expected to increase patient compliance and improve the efficacy of artificial tears in the treatment of dry eyes. Summary of the invention
[0007] In order to solve the multiple causes of the vicious cycle of dry eyes and the shortcomings of traditional artificial tears, a new type of artificial tears with long retention on the ocular surface and multifunctionality is developed. The present invention provides a copolymer artificial tear with both ocular surface adhesion and antioxidant properties and its application. It has long ocular surface retention, wetting and antioxidant functions, thereby improving the efficacy of dry eye treatment, and is expected to become a new type of efficient and safe artificial tears.
[0008] The technical solution adopted by the present invention is: a copolymer artificial tear with both ocular surface adhesion and anti-oxidation properties, wherein the copolymer artificial tear is composed of a hydrophilic unit that provides a moisturizing function, a phenylboronic acid-sialic acid dynamic binding unit that specifically binds to sialic acid on the ocular surface mucin, and an antioxidant unit that relieves oxidative stress on the ocular surface of dry eyes.
[0009] The hydrophilic unit is a superhydrophilic zwitterionic monomer, which is one or more of phosphorylcholine, carboxylic acid betaine and sulfonic acid betaine zwitterionic monomers.
[0010] The phenylboronic acid-sialic acid dynamic binding unit is a monomer containing a phenylboronic acid structural unit. The monomer containing a phenylboronic acid structural unit is one or more of (meth) acrylate or (meth) acrylamide monomers containing a phenylboronic acid structural unit.
[0011] The copolymer artificial tears are prepared by free radical copolymerization of super-hydrophilic zwitterionic monomers and monomers containing phenylboronic acid structural units.
[0012] The copolymer artificial tears are PMPD zwitterionic copolymers prepared by free radical copolymerization of super-hydrophilic zwitterionic 2-methacryloyloxyethyl phosphorylcholine (MPC) and monomer PBA-DHPM containing phenylboronic acid structural units.
[0013] The molar proportion of the phenylboronic acid-sialic acid dynamic binding unit in the copolymer artificial tears is 5-40%.
[0014] The molar proportion of the phenylboronic acid-sialic acid dynamic binding unit in the copolymer artificial tears is 20%.
[0015] An application of the copolymer artificial tears in preparing medicine for treating dry eyes.
[0016] The concentration of the copolymer artificial tears in the dry eye medicine is 1 mg / mL-20 mg / mL.
[0017] The beneficial effects of the present invention are as follows: the present invention provides a copolymer artificial tear with both ocular surface adhesion and anti-oxidation and its application, and develops a novel artificial tear with long ocular surface retention and multifunctionality for multiple causes of the vicious cycle of dry eye and the deficiencies of traditional artificial tears, which is expected to become an ideal solution for treating dry eye. The present invention develops a novel zwitterionic polymer artificial tear, the copolymer contains three functional units, the superhydrophilic zwitterion exerts the moisturizing function of artificial tears, PBA specifically binds to sialic acid on ocular surface mucin to achieve long ocular surface retention, and cooperates with the function of alleviating oxidative stress on the ocular surface of dry eye, which is expected to optimize the dry eye effect in a "one stone, three birds" manner, and provide new ideas for the development and utilization of novel multifunctional artificial tears. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 Schematic diagram of the principle of artificial tears treating dry eyes through a three-pronged approach of tear replenishment, ROS removal and ocular surface adhesion.
[0019] Figure 2 The molecular structure and 1 H NMR spectra.
[0020] Figure 3 (a) Solution appearance, (b) absorbance, and (c) transmittance of polymers with different PBA-DHPM molar ratios.
[0021] Figure 4 (a) Curve of polymer viscosity changing with shear rate (b) Polymer viscosity at a shear rate of 33.9 1 / s (ns indicates no statistical difference compared with the PMPC 10 mg / mL group; ## indicates P < 0.01).
[0022] Figure 5 (a) Schematic diagram of the reaction in which free ARS is released when SA and ARS competitively bind to PMPD, (b) macroscopic images and (c) UV-visible absorption spectra of ARS, ARS-PMPC, ARS-PMPD, and mixed solutions of ARS-PMPD and SA in different proportions.
[0023] Figure 6 (a) Shear rate curve after polymer and mucin were mixed (b) Viscosity of the mixed solution of polymer and mucin at a shear rate of 33.9 1 / s (ns indicates no statistical difference, *** indicates P < 0.001, compared with the PBS + Muc group) Figure 7 The effects of different concentrations of PMPC, PMPD (5%), and PMPD (20%) on (a) ABTS + 、(b)DPPH·、(c)O2 ·- , (d) OH radical scavenging rate.
[0024] Figure 8 (a) HCEC cultured in medium containing PMPD for 24 h, (b) HCEC cultured in medium containing PMPD for 48 h, (c) HCJEC cultured in medium containing PMPD for 24 h, (d) cell survival rate of HCJEC cultured in medium containing PMPD for 48 h.
[0025] Fig. 9The scratch healing ability of HCEC in polymer culture medium solutions with different PBA-DHPM molar ratios (a) Microscope image (b) Statistical results (* indicates P < 0.05, *** indicates P < 0.001, compared with the control group; # indicates P < 0.05, # indicates P < 0.001).
[0026] Fig.10 The protective effects of PMPC, PMPD (5%), and PMPD (20%) on cell drying stress (a) CCK-8 results and (b) live / dead staining results (c) comparison of cell morphology after drying modeling with the normal group and modeling group (ns indicates no statistical difference, *** indicates P < 0.001, compared with the Dry control group; ## indicates P < 0.01).
[0027] Fig.11 (a) Survival rate of HCEC after treatment with different concentrations of H2O2 (b) Survival rate of HCEC after treatment with mixed culture medium of H2O2 and polymer (c) Live / dead staining of HCEC after co-culture with H2O2 and polymer (ns indicates no statistical difference; * indicates P<0.05, *** indicates P<0.001, compared with the H2O2 group; ## indicates P<0.01).
[0028] Fig.12 The DCFH-DA probe method was used to detect the intracellular ROS levels in different groups. (a) Microscope image (b) Immunofluorescence intensity statistical graph (ns indicates no statistical difference, *** indicates P < 0.001, which is the result compared with the Control group; ## indicates P < 0.01, and ### indicates P < 0.001).
[0029] Fig.13 Slit lamp diffuse light observation for animal safety evaluation of PMPC and PMPC (20%): (a) frontal (b) lateral (c) narrow light band observation.
[0030] Fig.14 Sodium fluorescein staining was used to evaluate the animal biosafety of PMPC and PMPC (20%).
[0031] Fig.15 The intraocular pressure was monitored after instillation of PBS, PMPC, and PMPC (20%).
[0032] Fig.16 PAS staining after PMPC and PMPD (20%) were applied to the eyes (bar: 50 μm).
[0033] Fig.17(a) Fluorescence imaging of the ocular surface of mice after 0 and 15 min of eye application of fluorescent molecule-labeled FL-PMPC, FL-PMPD (5%), and FL-PMPD (20%); (b) Metabolic statistics of FL-PMPC, FL-PMPD (5%), and FL-PMPD (20%) on the ocular surface 15 min later (** indicates P < 0.01, *** indicates P < 0.001, compared with the PMPC group; # indicates P < 0.05) Fig.18 The mouse ocular surface dryness model and the ocular surface sodium fluorescein staining of different groups after modeling: (a) slit lamp image under cobalt blue light (b) statistical results of sodium fluorescein staining score (ns indicates no statistical difference, *** indicates P < 0.001, compared with the DryControl group; ### indicates P < 0.001). DETAILED DESCRIPTION
[0034] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0035] The present invention is based on the common C=C structure of PBA-DHPM and MPC monomers, and copolymerizes to synthesize PMPD polymers with different PBA-DHPM molar ratios. The chemical structure and molecular weight are verified by nuclear magnetic resonance and GPC tests. Its physical properties such as transmittance and viscosity are measured. The ocular surface retention effect of the polymer is evaluated by using sialic acid binding experiments and observing the ocular surface metabolism of FL-PMPD polymer mice through fluorescent group modification; free radical scavenging experiments, cell H2O2 damage protection and intracellular ROS scavenging are used to prove that the polymer plays a protective role against cell oxidative stress damage; then, its biocompatibility is studied at the cell and animal levels. The comprehensive therapeutic effect of PMPD polymer on dry eye is verified by using cell and animal dry injury models.
[0036] Example 1: Synthesis of polymers with different PBA-DHPM molar ratios and PMPD polymers 1 H NMR spectrum analysis and molecular weight Based on the degree of polymerization of 100, the molar proportions of PBA-DHPM were 0%, 5%, and 20%, respectively, to synthesize PMPC, PMPD (5%), and PMPD (20%) polymers.
[0037] like Figure 2As shown, the chemical attribution of each peak can be clearly observed, including the characteristic peak -CH2-C(CH3) of MPC (δ3.78ppm, 4) and the characteristic peaks of benzene ring of PBA-DHPM (δ7.45, 7.70, 7.92ppm, 10). By comparing the area of the characteristic peak of benzene ring of PBA-DHPM (10) with the area of the characteristic peak of MPC (4 or 5), the molar percentage of PBA-DHPM in the copolymer was calculated to be 0%, 3.97%, and 18.4%, respectively, which is very close to the 0%, 5%, and 20% of the feed, which is in line with expectations.
[0038] The molecular weight and distribution of PMPD were characterized by aqueous GPC. As shown in Table 1, PMPC, PMPD (5%) and PMPD (20%) have similar molecular weights. As the PBA-DHPM ratio increases, the polymer molecular weight increases slightly. The PDI values of the three copolymers are relatively close, all around 2.2-2.5. The larger PDI values are because the copolymers all use a simple uncontrolled free radical polymerization method.
[0039] Table 1 PMPD relative molecular weight and molecular weight distribution
[0040] Example 2: Light Transmittance of PMPD Polymer Solution First, place the sample solution in an eye drop bottle, and qualitatively observe and compare the clarity of the icon below the solution. Figure 3 (a) It can be seen that the icons of each group are clearly visible when observed through the solution, and there is no significant difference between the groups when viewed with the naked eye.
[0041] Furthermore, the ultraviolet absorbance and transmittance of the polymer solution were quantitatively measured by an ultraviolet spectrophotometer. Figure 3 As shown in (b), in the visible light range (400-800 nm), the overall absorbance of the polymer solution is less than 10% and the transmittance is greater than 90% within the concentration range of 10 mg / mL. For the same concentration of polymer, in the range of 400-500 nm, as the molar ratio of PBA-DHPM increases, the absorbance increases accordingly, which should be related to the unsaturated structure such as benzene ring contained in PBA-DHPM.
[0042] Example 3: Viscosity of PMPD polymer solution The viscosity of the polymer solution was measured using the rheometer in shear rate sweep mode. Figure 4 As shown in (a), the viscosity of PMPC, PMPD (5%), and PMPD (20%) solutions gradually decreases with increasing shear rate, showing shear thinning characteristics. Figure 4(b) Statistical comparison of the viscosity differences of PMPC, PMPD (5%), and PMPD (20%) at physiological blink shear rate (33.9 1 / s) showed that the viscosity of the polymer solution was not related to the molar ratio of PBA-DHPM (P>0.05). When the concentration of PMPD (20%) varied from 1 to 5 mg / mL, the viscosity did not change with the increase of polymer concentration (P>0.05). When the concentration of PMPD (20%) was 10 mg / mL, the viscosity of the polymer solution increased slightly, which was statistically significant (P<0.01).
[0043] Example 4: Evaluation of sialic acid binding ability of PMPD polymers like Figure 5 As shown in (a), ARS has a catechol structure and can react with phenylboronic acid to form phenylboronic acid ester; when sialic acid (SA) is added, SA and ARS compete with phenylboronic acid to react, and ARS is released again. This reaction process can be manifested as changes in the solution color and UV-visible light absorption spectrum. Figure 5 As shown in (b) and (c), ARS has a characteristic absorption peak in the UV-visible spectrum, and the solution color is purple-red; after PMPD is added to the ARS solution, the solution color turns yellow and the UV-visible spectrum blue-shifts, indicating that it reacts with ARS; while when PMPC is added to ARS, the solution color and spectral position do not change, indicating that no reaction occurs. Then, SA is added to the mixed solution of ARS and PMPD. As the SA ratio increases, the solution color gradually changes from light yellow to purple-red. The higher the SA ratio, the closer the purple-red color is to the ARS color, and the corresponding absorption peak position continues to red-shift, gradually approaching the peak position of the ARS solution. The above results show that PMPD can form a phenylboronic acid ester bond with SA diol through the PBA group.
[0044] Example 5: Evaluation of Mucin Binding Ability of PMPD Polymers The interaction between polymer and mucin was evaluated by rheological viscosity test. Figure 6 As shown, the shear rate is between 1 and 100 s -1 When the ratio of PBA to DHPM was between 20% and 10%, the viscosity of the mixed solution of PMPD (20%) and Muc was significantly greater than that of the mixed solution of PMPD (5%), PMPC, and PBS and mucin (Figure (a) and Figure (b)). The above results show that PMPD copolymer can interact with mucin, and as the proportion of PBA-DHPM increases to 20%, the interaction increases rapidly. It is inferred that the PBA in PMPD and the mucin sialic acid residues form phenylboronic acid cross-links, thereby significantly increasing the viscosity of the mixed solution.
[0045] Example 6: Evaluation of the Antioxidant Capacity of PMPD Polymers The present invention uses polymer to treat ABTS+ 、DPPH·、O2 ·- The scavenging ability of free radicals such as ·OH was determined to evaluate the effects of PBA-DHPM ratio and polymer concentration on the antioxidant capacity of the polymer.
[0046] PMPC, PMPD (5%), PMPD (20%) and ABTS working solution were mixed at a volume ratio of 1:20. Figure 7 As shown in (a), for the same PBA-DHPM molar ratio, the higher the polymer concentration; for the same polymer concentration, the higher the PBA-DHPM molar ratio, the better it is at removing ABTS + The more, the faster. Therefore, the total antioxidant capacity increases with the increase of PBA-DHPM molar ratio and concentration. At 30 min, ABTS + The free radical scavenging rate is about 96.6%.
[0047] PMPC, PMPD (5%), PMPD (20%) and 0.15 mM DPPH working solution were mixed in a 1:1 volume ratio, e.g. Figure 7 (b) Same as ABTS + The free radical scavenging law shows that the scavenging rate increases with the molar ratio of PBA-DHPM and the polymer concentration. However, the scavenging rate of DPPH free radicals is lower than that of ABTS. + The free radical scavenging rate was slow. The DPPH free radical scavenging rate of 10 mg / mL PMPD (20%) polymer reached about 65.2% in 20 h.
[0048] The solution of NBT, riboflavin and MET mixed is light yellow. After ultraviolet irradiation, oxygen free radicals are generated and the solution color turns dark purple. The lighter the color, the higher the O2 ·- The result is as follows Figure 7 (c) shows that the free radical scavenging rule is the same as ABTS + Clearance rules. PMPD (20%) to O2 ·- The scavenging ability is the strongest, at 10 mg / mL, it has a strong ability to remove O ·- The clearance rate was about 93.5%.
[0049] Ferrous ions reduce H2O2 to produce ·OH free radicals, and the non-fluorescent molecule TA captures ·OH and transfers it to the fluorescent probe 2-hydroxyterephthalic acid, which is quantitatively detected using a fluorescence spectrophotometer. The scavenging rules of PBA-DHPM are the same as those of ABTS + The removal rules showed that PMPD (20%) had a strong removal effect on ·OH, and 10 mg / mL had a strong removal effect on O2 ·- The clearance rate was about 80.1%.
[0050] In summary, the effect of polymer PMPD on ABTS + 、DPPH·、O2 ·- , ·OH all have scavenging effects. The higher the molar proportion of PBA-DHPM and the higher the polymer concentration, the stronger the scavenging effect is, and it is time-dependent.
[0051] Example 7: Evaluation of Cellular Biocompatibility of PMPD Polymers (1) CCK-8 experiment The biocompatibility of PMPC, PMPD (5%), and PMPD (20%) polymers on human corneal epithelial cells HCEC and human conjunctival epithelial cells HCJEC was detected by CCK-8 experiment. The polymer concentration range was set to 0.1, 0.2, 0.5, 1, 2, 5, and 10 mg / mL. HCEC and HCJEC cells were cultured in different PBA-DHPM molar ratios and different polymer concentrations for 24 h and 48 h, and the cell survival rate was greater than 80%. It met the threshold of ISO / EN 10993-5 standard (>70% cell viability), indicating that PMPC, PMPD (5%), and PMPD (20%) have good biocompatibility with HCEC and HCJEC cells within the concentration range of 10 mg / mL.
[0052] Example 8: Cell scratch assay The healing of corneal epithelial injury is an important sign of dry eye improvement. Therefore, the biocompatibility and cell migration-promoting ability of PMPC, PMPD (5%), and PMPD (20%) were evaluated by corneal epithelial cell scratch test. Fig. 9 As shown, after 24 hours of culture in the polymer solution, the cell migration rate increased with the increase of the molar proportion of PBA-DHPM, indicating that PMPC and PMPD polymers, especially the PMPD polymer copolymerized with PBA-DHPM, have good biocompatibility and ability to promote cell migration.
[0053] Example 9: Cell Drying Stress Model and Protective Effect of PMPD Polymer like Fig.10 As shown in (a), after the culture medium solution was removed and the cells were dried in a fume hood for 30 min, the cell survival rate dropped to about 4.1%, indicating that the cell drying model was successfully established. In the experimental group, PMPC, PMPD (5%), and PMPD (20%) were incubated with HCEC for 4 h, and then the polymer culture medium solution was removed for drying and modeling. The results showed that the cell survival rates of the PMPD (20%) and PMPD (5%) groups were significantly higher than those of the modeling group (all P<0.001), and the PMPD (20%) group was higher than the PMPD (5%) group (P<0.01). Fig.10As shown in (b), the live / dead staining results are consistent with the CCK-8 results, and PMPD (20%) has the highest live cell density. In summary, PMPC did not copolymerize with PBA-DHPM, and after absorbing the culture medium, it did not remain on the cell surface, and could not provide protection against cell drying stress in this experiment. At the same time, when PBA-DHPM copolymerized at 20%, PMPD had the strongest synergistic effect on cell adhesion and moisturizing, and played the strongest role in protecting cells from drying stress damage.
[0054] like Fig.10 As shown in (c), this experiment used the bright field mode of the microscope to observe the differences in cell morphology after modeling in different groups. Compared with the control group, the cell morphology of the modeling group and the PMPC group was shrunken and necrotic. The cell morphology of the PMPD (5%) group was not as stretched as that of the PMPD (20%) group, and the degree and proportion of cell shrinkage were greater than those of the PMPD (20%) group. This once again shows that PMPD (20%) has a synergistic adhesion and moisturizing effect, which plays a protective role against cell drying stress.
[0055] Example 10: Assessment of antioxidant capacity at the cellular level (1) H2O2IC50 After HCEC were treated with different concentrations of H2O2 for 4 h, the survival rate of HCEC was detected using CCK-8. Fig.11 As shown in (a), the cell survival rate showed a concentration-dependent decrease trend. When the H2O2 concentration was 300 μM, the cell survival rate was closest to 50%. Therefore, 300 μM was used to create the HCEC H2O2 injury model.
[0056] (2) H2O2 injury protection - CCK-8 experiment After HCECs were co-cultured with PMPC, PMPD (5%), and PMPD (20%) polymers and H2O2 (300 μM), CCK-8 was used to detect the survival rate of HCECs, and the protective effects of polymers with different PBA-DHPM molar ratios on HCEC H2O2 damage were compared. Fig.11 As shown in (b), the cell survival rate of the 300μM H2O2 modeling group was about 50%, which was consistent with expectations; there was no statistical difference in cell survival rate between the PMPC group and the modeling group (P>0.05), indicating that the antioxidant effect of PMPC was not obvious; the cell survival rates of the PMPD (5%) and PMPD (20%) groups were significantly higher than those of the modeling group (P<0.05), indicating that the PMPD polymer copolymerized with PBA-DHPM has the effect of protecting cells from H2O2 damage; the cell survival rate of the PMPD (20%) group was significantly higher than that of PMPD (5%) (P<0.01), indicating that as the molar proportion of PBA-DHPM increases, the protective effect against oxidative damage to cells becomes stronger.
[0057] (3) Intracellular ROS clearance experiment In order to further detect the protective effect of the polymer solution on HCEC oxidative stress damage, the DCFH-DA fluorescent probe was used to detect the level of ROS in the cytoplasm. DCFH-DA decomposes into DCFH after entering the cell, and DCFH is oxidized into DCF, emitting green fluorescence. The results are shown in Fig.12 As shown in the figure, in the modeling group, after culturing cells with H2O2 (200μM) for 4h, the level of intracellular green fluorescence was significantly enhanced, indicating that the level of ROS in the cytoplasm of the modeling group increased and the modeling was successful. In the experimental group, there was obvious green fluorescence in the cytoplasm of HCEC in the PMPC group, and the level of ROS increased significantly; the green fluorescence in the PMPD (5%) group weakened; the green fluorescence intensity in the PMPD (20%) group was close to that of the control group. The results showed that as the molar proportion of PBA-DHPM increased, the ability of PMPD to scavenge H2O2 increased, which reduced the level of ROS in the cells.
[0058] In summary, PMPD polymer has the effect of scavenging free radicals, while PMPC has almost no scavenging effect. The higher the PBA-DHPM ratio, the stronger the ability of the polymer to scavenge free radicals, and PMPD (20%) exhibits the strongest antioxidant capacity at the cellular level.
[0059] Example 11: Animal Safety Evaluation (1) Slit lamp observation Slit lamp observation results Fig.13 As shown, the corneal epithelium of each group was intact, clear, transparent, without edema or defect; the conjunctiva had no congestion or edema; there was no ciliary congestion or ocular surface inflammatory exudation. There were no acute or chronic irritation symptoms on the ocular surface of mice.
[0060] (2) Observation by fluorescein sodium staining like Fig.14 As shown in the figure, the ocular surface of mice in the PBA, PMPC and PMPD (20%) groups showed no obvious staining or only a small amount of staining, indicating that the corneal epithelial structure was intact, without ulcers and defects, and without acute or chronic irritation symptoms. (3) Intraocular pressure like Fig.15 As shown in the figure, there was no statistical difference in intraocular pressure between groups (PBS, PMPC, PMPD (20%) groups) and within groups (time) (P>0.05), indicating that during the eye drops, the intraocular pressure of mice did not fluctuate significantly and was stable in the range of 10-12 mmHg. PMPC and PMPD (20%) eye drops did not have an adverse effect on the intraocular pressure of mice.
[0061] (4) PAS staining On the 7th day, the eyeballs of the mice were removed with eyelids removed and PAS staining was performed. Fig.16The goblet cell density of mice in PMPC and PMPD (20%) groups was consistent with that in PBS group and was closely arranged.
[0062] In summary, PMPC and PMPD (20%) have good animal biosafety for ocular application at a concentration of 10 mg / mL.
[0063] Example 12: Animal ocular surface retention evaluation Fluorescence-modified FL-PMPC, FL-PMPD (5%), and FL-PMPD (20%) polymers were used to observe the fluorescence clearance metabolism, that is, the retention capacity of different polymers on the ocular surface, using small animal in vivo imaging. Fig.17 As shown in the figure, 15 minutes after the polymer was applied to the eye, the residual fluorescence intensity of the ocular surface in the PMPD (20%) group was stronger than that in the PMPD (5%) group (P<0.05), and the residual fluorescence intensity of the ocular surface in the PMPD (5%) group was stronger than that in the PMPC group (P<0.01). The results showed that the higher the proportion of PBA-DHPM, the longer the polymer stayed on the ocular surface.
[0064] Example 13: Animal ocular surface dryness stress model and protective effect of polymers The results are as follows Fig.18 As shown in the figure, before the experiment, there was no obvious or only a small amount of sodium fluorescein staining on the ocular surface of the mice, indicating that all mice had healthy ocular surfaces. In the modeling group, there was obvious large-scale sodium fluorescein staining on the ocular surface of the mice, indicating that the mouse ocular surface dryness model was successfully established. In the PBS and commercial PEG groups, as in the modeling group, there was obvious large-scale sodium fluorescein staining on the ocular surface (P>0.05). In the PMPC group, the sodium fluorescein staining on the ocular surface was reduced, which was statistically significant compared with the modeling group (P<0.001). The sodium fluorescein staining in the PMPD (20%) group was lighter than that in the PMPC group (P<0.001). Therefore, the copolymerization of PBA-DHPM enables PMPD (20%) to adhere to the ocular surface and play an anti-dryness injury role.
[0065] in conclusion (1) The present invention successfully prepared PMPD zwitterionic copolymers through free radical polymerization. The light transmittance of the solution is basically above 90%, the viscosity is similar to that of natural tears, and it has shear thinning characteristics, making it suitable as artificial tears.
[0066] (2) PMPD copolymers have good free radical scavenging function. At the cellular level, the function of PMPD copolymers in scavenging free radicals and protecting cells from oxidative stress damage was verified by the H2O2-induced oxidative stress model.
[0067] (3) Thanks to the specific diol binding ability of PBA, the ability of PMPD copolymer to bind to sialic acid to form a phenylboronic acid ester bond was verified by the ARS method. The rheological viscosity test confirmed that PMPD copolymer has a stronger mucin binding ability. Furthermore, at the animal level, it was confirmed that PMPD copolymer has a longer ocular surface retention time.
[0068] (4) Benefiting from the superhydrophilicity of zwitterions and the combined ocular surface binding and antioxidant functions of PBA, PMPD copolymers showed excellent cell protection and ocular surface moisturizing functions in cell and animal dryness models.
[0069] (5) At the cellular and animal levels, PMPD was confirmed to be an artificial tear material with good biocompatibility.
[0070] In summary, PMPD copolymer can be used as a new type of multifunctional artificial tears, based on the triple functions of "wetting, ocular surface adhesion, and anti-oxidation", to achieve efficient dry eye treatment. Compared with the shortcomings of commercial artificial tears with a single function, this invention is expected to provide new ideas for the development of the next generation of artificial tears.
[0071] The above are only preferred embodiments of the present invention, and the protection scope of the present invention is not limited to the above embodiments. All technical solutions under the concept of the present invention belong to the protection scope of the present invention. It should be pointed out that for ordinary technicians in this technical field, some improvements and modifications without departing from the principle of the present invention should be regarded as the protection scope of the present invention.
[0072] Technical personnel should note that although the present invention has been described according to the above specific implementation methods, the inventive concept of the present invention is not limited to this invention, and any modification using the inventive concept will be included in the scope of protection of this patent.
Claims
1. A copolymer artificial tear having both ocular surface adhesion and anti-oxidation properties, characterized in that: The copolymer artificial tears are composed of a hydrophilic unit providing a moisturizing function, a phenylboronic acid-sialic acid dynamic binding unit specifically binding to sialic acid on the ocular surface mucin, and an antioxidant unit relieving oxidative stress on the ocular surface of dry eyes.
2. The copolymer artificial tear having both ocular surface adhesion and anti-oxidation properties according to claim 1, characterized in that: The hydrophilic unit is a superhydrophilic zwitterionic monomer, and the superhydrophilic zwitterionic monomer is one or more of phosphorylcholine, carboxylic acid betaine and sulfonic acid betaine zwitterionic monomers.
3. The copolymer artificial tear having both ocular surface adhesion and anti-oxidation properties according to claim 1, characterized in that: The phenylboronic acid-sialic acid dynamic binding unit is a monomer containing a phenylboronic acid structural unit.
4. The copolymer artificial tear having both ocular surface adhesion and anti-oxidation properties according to claim 3, characterized in that: The monomer containing phenylboronic acid structural unit is one or more of (meth)acrylate or (meth)acrylamide monomers containing phenylboronic acid structural unit.
5. The copolymer artificial tear having both ocular surface adhesion and anti-oxidation properties according to claim 1, characterized in that: The copolymer artificial tears are prepared by free radical copolymerization of super-hydrophilic zwitterionic monomers and monomers containing phenylboronic acid structural units.
6. The copolymer artificial tear having both ocular surface adhesion and anti-oxidation properties according to claim 5, characterized in that: The copolymer artificial tears are PMPD zwitterionic copolymers prepared by free radical copolymerization of super-hydrophilic zwitterionic 2-methacryloyloxyethyl phosphorylcholine (MPC) and monomer PBA-DHPM containing phenylboronic acid structural units.
7. The copolymer artificial tear having both ocular surface adhesion and anti-oxidation properties according to claim 1, characterized in that: The molar proportion of the phenylboronic acid-sialic acid dynamic binding unit in the copolymer artificial tears is 5-40%.
8. The copolymer artificial tear having both ocular surface adhesion and anti-oxidation properties according to claim 7, characterized in that: The molar proportion of the phenylboronic acid-sialic acid dynamic binding unit in the copolymer artificial tears is 20%.
9. Use of the copolymer artificial tears according to claim 1 in preparing a drug for treating dry eyes.
10. The use according to claim 9, characterized in that: The concentration of the copolymer artificial tears in the dry eye medicine is 1 mg / mL-20 mg / mL.
Citation Information
Cited By
Artificial tear simulating multi-layer structure of tear film as well as preparation and application of artificial tear
CN121221526A
